Articles tagged with Cancer Medication
Researchers at Einstein College of Medicine made notable advances in understanding and treating cancer, including new discoveries about nerve cells, cancer-causing genes and epigenetics. They will present their work at the AACR Annual Meeting.
A phase 1 trial found ceritinib to be highly effective against both crizotinib-sensitive and resistant tumors with manageable side effects. The study enrolled 130 participants and showed dramatic shrinkage in tumor size and number in around 60% of patients.
Immunotherapy has shown huge potential in treating lung cancer by preventing tumour cells from escaping the immune system. New data on immunocheckpoint regulators such as PD-1 and PD-L1 have resulted in impressive global overall response rates of 20% to 25%.
Researchers are searching for a hepatitis B cure drug using a new assay and partnering with robots to screen thousands of potential candidates. The goal is to find a treatment that can halt the illness, as current drugs only treat it.
A new study has developed a revolutionary new drug called ZL105 that manipulates the body's natural energy systems to attack and shut down cancerous cells. The compound is based on the precious metal iridium and may be ten times more effective in treating various types of cancers.
A study at Dana-Farber Cancer Institute found wide variation in oncologists' attitudes towards offering cancer gene testing, with those having high genomic confidence more likely to prescribe the test. The survey revealed that 42% of doctors approved telling patients about uncertain test results, highlighting concerns about delivering ...
A study of 439,628 veterans found that taking Valproic acid for at least one year lowered the risk of developing head and neck cancer by 34%. Higher doses and longer durations of use provided additional benefits with up to 16,000 new cases potentially prevented annually in the US.
Researchers at Massachusetts General Hospital have identified a path to safer drugs for heart disease and cancer. By analyzing the structure of an extracellular matrix protein and its interaction with an integrin, they have discovered a high-affinity version that can bind strongly without inducing unintended receptor activation.
A novel simulation-based approach has been used to find and evaluate new potential drugs for liver cancer, identifying 101 compounds predicted to prevent cancer growth in most patients. The researchers simulated the effect of over 3,000 antimetabolites on healthy cells to predict their toxic effects.
A multidisciplinary research team has developed a new approach, E2E Clinical Trials, which aims to improve the accuracy of treatment selection by seamlessly transitioning from controlled efficacy trials to real-world effectiveness trials. This continuum will provide better understanding of treatment effects on diverse patient populations.
Researchers at TGen identified the ALK-EML4 gene fusion as the genetic driver of an aggressive type of thyroid cancer. The study's findings suggest that this fusion can be targeted with existing drug crizotinib, offering a new treatment option for patients with radioiodine-resistant aggressive papillary thyroid cancer.
A study published in the Journal of Leukocyte Biology found that histamine plays a role in protecting tumors from the immune system. By blocking histamine production, researchers were able to interrupt a process promoting melanoma growth.
Researchers have identified a key pathway that helps cancer cells survive in low-glucose environments, and found that certain diabetes drugs can inhibit this pathway to kill cancer cells. The study provides new insights into how anti-cancer properties of diabetes drugs like metformin may work.
Scientists have discovered two novel genes linked to angiosarcoma, a rare and aggressive cancer of blood vessels. The study found that these genes are mutated in nearly 40% of cases, suggesting potential new targets for treatment.
Researchers have developed a novel approach to treating CLL by disrupting the activity of the NF-kappaB pathway, which ensures survival and resistance of CLL cells. This approach may lead to re-sensitization of CLL cells to conventional chemotherapy and novel agents.
A phase I trial found a complete response for 14 months to everolimus and pazopanib in a patient with advanced bladder cancer and rare mTOR genetic mutations. Genomic profiling revealed two alterations that activated the mTOR-mediated cell signaling pathway, rendering the cancer sensitive to the mTOR inhibitor.
Researchers identify two rare mutations in the mTOR gene associated with a complete response to everolimus and pazopanib, leading to improved treatment options for patients. The study provides new insights into personalized medicine and targeted therapies for bladder cancer.
Researchers developed a novel therapy combining cryoablation with nanodrug chemotherapy to eliminate cancer stem-like cells. The treatment showed significant promise in eradicating CSCs, reducing the risk of cancer recurrence and metastasis. This innovative approach has great potential for improving cancer treatment outcomes.
A new clinical study found that erlotinib significantly improved treatment outcomes for women with locally advanced cervical cancer. After two years, 91.7% of patients were alive and experienced no disease progression.
Researchers found that several chemotherapy drugs cause hyper proliferation in stem cells, leading to tumor recurrence. The study used fruit flies as a model, discovering compounds that inhibit tumors without causing this side effect.
A study by The Institute of Cancer Research identified mutations in the DNA methyltransferase gene, DNMT3A, in 13 children with a newly described condition called 'DNMT3A overgrowth syndrome'. The condition causes intellectual disability and unusual growth in children, but has no link to cancer risk.
Researchers have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma. The finding is based on shRNA technology that identifies genes required for glioblastoma growth and reveals surprising links to dopamine regulation, a crucial component in treating Parkinson's disease and schizophrenia.
A new study published in Circulation reveals how changes in the organized cell membrane network of heart muscle leads to heart failure. Colchicine, a drug used for gout treatment, protects normal heart function by reducing microtubule density, while taxol accelerates damage during heart failure.
Researchers at UT Southwestern Medical Center have identified a key protein target for shutting down the growth of prostate cancer cells. ERG protein is transformed into cancer cells by an enzyme called USP9X, but a molecule called WP1130 can block this process.
Patients receiving nivolumab survived for an average of 16.8 months, with 62% alive one year after treatment initiation and 43% alive two years later. The drug also shrank tumors in 31% of patients, with some able to remain on the treatment for up to two years.
A new study by Dana-Farber Cancer Institute and Johns Hopkins University found that an immune system-based therapy called nivolumab can produce lasting remissions in melanoma patients, with some patients remaining alive after two years without treatment. The therapy has been shown to block PD-1, a protein that restrains the immune syst...
Researchers at Norris Cotton Cancer Center have developed an antibody that targets the ProAVP surface marker in small-cell lung cancer. The antibody, MAG-1, significantly slows tumor growth in mice and has shown promise as a potential treatment for recurrent small-cell lung cancer.
Researchers have found that an ancient Chinese medicine extract blocks pathways to treat pancreatic cancer by inhibiting scarring and inflammation. The compound also appears to suppress Cox-2, an enzyme that causes inflammation, and has been shown to be safe for use in patients.
A new study comparing prescription data from England and Wales has found that patients in England are up to seven times more likely to be prescribed expensive cancer drugs than their counterparts in Wales. The Cancer Drugs Fund has created an inequality in access to these treatments, raising ethical, moral, financial, and policy concerns.
Researchers have developed a new laboratory screening technique to find novel treatments for pediatric neuroblastoma. MicroRNAs play an important role in regulating cell development and differentiation, revealing promising targets for new therapies.
Researchers developed nanoparticles that absorb energy from infrared red wavelength and release chemotherapy drugs when triggered by two-photon laser. The delivery system shows promise for treating cancer with reduced treatment side effects and increased cancer-killing effect.
A randomized, double-blind trial of 621 adults found that Bevacizuman did not prolong survival for newly diagnosed glioblastoma patients. The results contradict earlier studies showing the drug's effectiveness in other diseases.
A new protein called Merm1 has been discovered to play a role in controlling cell growth and division in lung tissue. This finding could lead to the development of new drugs targeting lung cancer.
A UCLA research team has developed a treatment that blocks two metabolic pathways needed by leukemia cells, halting their growth and leading to cell death. The experimental treatment showed promising results in mice with acute lymphoblastic leukemia.
The American Academy of Pediatrics (AAP) has updated its policy on the off-label use of drugs in children, offering guidance for physicians to ensure safe and effective treatment. The new recommendations aim to improve drug safety and efficacy in pediatric patients, particularly those with special needs or rare diseases.
Researchers at Tel Aviv University propose a new nanoscale drug-delivery system to tackle aggressive ovarian cancer using a cluster of nanoparticles called gagomers. The system accumulates in tumors, producing dramatic therapeutic benefits and reducing toxic accumulation in healthy organs.
Researchers found that a cancer medication reduces sudden cardiac death risk in mice with abnormal heartbeats and heart failure. This promising treatment option could provide patients and clinicians with a new paradigm for treating life-threatening illness.
A Phase III clinical trial found no significant improvement in overall survival or progression-free survival with bevacizumab treatment for new glioblastoma patients. Researchers also observed increased symptoms and neurocognitive decline among non-progressing patients treated with bevacizumab.
A University of Colorado study used a COXEN model to match tumors with optimal drugs, significantly extending patient survival. The model analyzed genetic data from thousands of tumor samples to identify response patterns.
A four-year clinical study involving 461 patients with advanced cancers showed that earlier palliative care significantly improved quality of life and patient satisfaction. The study demonstrated the benefits of cancer centers providing early specialized palliative care in outpatient clinics.
Researchers aim to develop nanoparticles that target prostate cancer cells with a genotoxin drug. The nanoparticles will also promote healing in damaged blood vessels by mimicking platelets and catching circulating endothelial progenitor cells.
A pre-clinical study suggests that dinaciclib, a CDK inhibitor, can improve the effectiveness of certain therapies for multiple myeloma and myeloid leukemia by disrupting the unfolded protein response (UPR) in cancer cells. The UPR is a cell survival mechanism that allows cancer cells to combat damage caused by anti-cancer agents.
A new method for purifying peptide-based drugs has been developed by a chemist at Michigan Technological University, separating perfect peptides from those that don't make the grade in just two hours. The process reduces waste and is cheaper than existing methods, offering a promising alternative for treating diseases like cancer and HIV.
Cancer doctors can cut costs without risk to patients by improving end-of-life care, reducing unnecessary medical imaging, and negotiating lower prices for new cancer drugs. These changes can save billions of dollars in healthcare spending while maintaining quality of life.
A study found tamoxifen, a breast cancer treatment, in three out of four samples of the bodybuilding supplement Esto Suppress. The product label suggested a dosage that may provide enough to treat gynaecomastia. Off-the-shelf supplements have been known to contain pharmacologically active substances, posing risks to users.
Researchers have discovered how the protein Bcl-2 signals cancer cells to live longer by altering calcium ion levels. This breakthrough could lead to new drugs targeting Bcl-2 and improve cancer treatment outcomes.
University of Pittsburgh Cancer Institute scientists have found several potential possibilities to try if the cancer becomes resistant to standard drug treatment. They discovered that high-throughput screening of already FDA-approved drugs can identify new therapies that could be rapidly moved to the clinic.
The 'Viewpoint' article highlights the complexity of developing genome-based therapeutics and companion diagnostics, which depend on multiple genetic tests. The authors argue for a unified plan to co-develop and co-submit diagnostic tests that predict drug benefit, addressing regulatory, business, and economic challenges.
Researchers discovered tamoxifen can kill Cryptococcus germ by interfering with a protein, offering potential new treatment for deadly brain infection. Additional animal experiments are needed to develop new anti-cryptococcal drugs based on the findings.
Researchers at UT Health Science Center identified a key role of the WTAP protein in AML development and found that suppressing it with Hsp90 inhibition greatly suppressed proliferation and induced differentiation. This discovery opens up new avenues for effective therapies for children and adults with newly diagnosed AML.
Researchers discovered tamoxifen, a breast cancer treatment, also kills Cryptococcus, a fungus causing deadly brain infections. The combination of tamoxifen and fluconazole was synergistic, showing improved activity against the fungus. This finding offers a new approach to treating cryptococcal meningitis.
A panel of 55 genes impacted by loss of protein SYK predicts invasive breast cancer, with better survival rates for patients without gene changes. Researchers found that 80% of patients without genetic alterations were still alive after 18 years, compared to 20% with gene changes.
Researchers at NYU Langone Health have found a biological weakness in mutant K-Ras, the most commonly mutated gene involved in human cancers. By blocking the activity of related genes H-Ras and N-Ras, chemotherapy drug irinotecan can stall tumor growth.
Researchers at Scripps Research Institute create Inforna, a technique to identify potent compounds targeting cancer-causing microRNAs. The method enables unprecedented targeting of disease-associated RNAs, offering a promising approach to designing novel anti-cancer drugs.
Researchers at CNIO propose a new combined therapy to treat cancer by combining etoposide with compounds that interfere with the cell cycle, increasing specificity and improving the therapeutic window. This approach aims to reduce toxicity and increase effectiveness in treating tumour cells.
Researchers have discovered that JAK inhibitors, currently used to treat blood disorders, can reduce the growth of inflammation-associated stomach and bowel cancer. The study provides evidence supporting their use in treating these cancers.
A group of experts has proposed concrete steps to prevent and manage drug shortages, including sharing scarce drugs and giving equal priority to patients. The 'blueprint for action' aims to move away from reactive strategies and focus on prevention, ensuring life-saving medications are accessible to children with cancer and beyond.
A single dose of rituximab significantly reduces kidney relapses in children and young adults with frequently-replapsing idiopathic nephrotic syndrome, allowing for discontinuation of standard immunosuppressive medications. The treatment is also well-tolerated and improves kidney function.
Researchers identified UHRF1 as a key driver of liver cancer in zebrafish models and human tumors, showing that high levels of UHRF1 can cause tumors to form rapidly. The study suggests that targeting UHRF1 could be an effective approach to halting cancer formation and offers new hope for treatments for hepatocellular carcinoma.
A new biological pathway-based computational model, called PHPN, mines large publicly available disease datasets to find shared genetic connections between diseases. The model offers a visual representation of the relationships between diseases and phenotype's at the systems level.